Novonesis (NSIS) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
18 Mar, 2026Executive summary
Achieved 7% organic sales growth for 2025, at the upper end of guidance, with volumes up ~7% and pricing and sales synergies each contributing about 1 percentage point, despite a 1% negative impact from exiting certain countries.
Adjusted EBITDA margin reached 37.1%, a 100bps improvement year-over-year, in line with outlook, despite significant currency headwinds.
Growth was broad-based and mainly volume-driven, supported by innovation and 33 new product launches, with ~25% of sales from products launched in the last 5 years.
Integration of the Feed Enzyme Alliance acquisition is progressing well, contributing positively to results.
Sustainability targets met, including 100% renewable electricity and 80% of sales aligned with at least one SDG.
Financial highlights
Reported sales grew 5% in EUR, with organic growth at 7%; currency headwinds were 3%, M&A contributed 1%.
Adjusted gross margin improved by 240 bps to 59.1% year-over-year, driven by lower input costs and productivity.
Adjusted EBITDA margin was 37.1%, up 100 bps from 2024, with cost synergies realized ahead of schedule.
Diluted adjusted EPS was EUR 1.49 (+16% YoY); EPS excluding PPA amortization was EUR 1.99 (+15% YoY).
Operating cash flow reached EUR 1.22 billion (+EUR 189 million YoY); free cash flow before acquisitions rose 15% to EUR 770 million (19% of sales).
CapEx was EUR 471 million (11.3% of sales), up 2 percentage points YoY, supporting production expansion.
Adjusted ROIC (excl. goodwill) was 10.1%, up from 8.3% pro forma 2024.
Outlook and guidance
2026 organic sales growth expected at 5%-7% (6%-8% excluding country exits), mainly volume-driven, with pricing and synergies each contributing ~1%.
Adjusted EBITDA margin guided at 37%-38%, with continued margin expansion despite ~50bps currency headwinds.
CapEx expected at 12%-14% of sales in 2026, reflecting temporary elevation for capacity expansion and ERP investments.
Net debt/EBITDA expected at 1.7x by year-end 2026.
Dividend payout proposed at DKK 6.5 (EUR 0.87) per share, a 58.4% payout ratio.
Effective tax rate expected at 22%-23% for 2026 and longer term.
Latest events from Novonesis
- 9% organic sales growth YTD 2024; full-year outlook raised to upper end of 7-8%.NSIS
Q3 202416 Feb 2026 - Upgraded 2024 outlook, 6%-8% growth, and margin expansion driven by synergies and innovation.NSIS
CMD 20243 Feb 2026 - 7% organic sales growth, margin gains, and innovation led to a raised 2024 outlook.NSIS
Q2 202423 Jan 2026 - Diversification and innovation drive growth in energy, with strong prospects in sustainable fuels.NSIS
Status Update11 Jan 2026 - Full control of animal biosolutions value chain drives growth, innovation, and margin gains.NSIS
M&A Announcement8 Jan 2026 - Double-digit Q1 growth, margin expansion, and a major acquisition support a strong outlook.NSIS
Q1 20258 Jan 2026 - 8% organic growth and 36.1% margin in 2024; 2025 outlook strong with synergies and innovation.NSIS
Q4 20247 Jan 2026 - Strong growth, integration, and sustainability marked the year; all AGM proposals were approved.NSIS
AGM 20257 Jan 2026 - Strong H1 growth, margin gains, and robust 2030 targets amid innovation and market expansion.NSIS
Q2 2025 & Strategy Update23 Nov 2025